ADGN-121

ADGN-121 is a preclinical gene editing therapeutic designed to target the KRAS G12D mutation, a common oncogenic driver in several solid tumors. Developed by Aanastra and Divincell SAS, this therapy utilizes proprietary RNA and peptide technology to achieve targeted gene editing of mutated oncogenes such as KRAS G12D. The approach involves delivering guide RNA (gRNAG12D) and mRNA encoding Cas9 to selectively disrupt or correct the mutant allele, thereby inhibiting tumor growth. Preclinical studies have demonstrated significant antitumor efficacy in models of pancreatic cancer (PANC-1 xenografts), including overcoming resistance to small molecule KRAS inhibitors like MRTX1133. The technology is positioned as an alternative strategy for patients with resistance to current small molecule therapies targeting KRAS mutations[1][3][6].